864543-80-6Relevant articles and documents
3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: Design and development to a highly selective lead
Soth, Michael,Abbot, Sarah,Abubakari, Allassan,Arora, Nidhi,Arzeno, Humberto,Billedeau, Roland,Dewdney, Nolan,Durkin, Kieran,Frauchiger, Sandra,Ghate, Manjiri,Goldstein, David M.,Hill, Ronald J.,Kuglstatter, Andreas,Li, Fujun,Loe, Brad,McCaleb, Kristen,McIntosh, Joel,Papp, Eva,Park, Jaehyeon,Stahl, Martin,Sung, Man-Ling,Suttman, Rebecca,Swinney, David C.,Weller, Paul,Wong, Brian,Zecic, Hasim,Gabriel, Tobias
scheme or table, p. 3452 - 3456 (2011/06/24)
Learnings from previous Roche p38-selective inhibitors were applied to a new fragment hit, which was optimized to a potent, exquisitely selective preclinical lead with a good pharmacokinetic profile.
p38 MAP kinase inhibitors and methods for using the same
-
Page/Page column 52-53, (2008/06/13)
Compounds of formula 1a or 1b: wherein A, W, X, Y, R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.
FUSED PYRAZOLE AS p38 MAP KINASE INHIBITORS
-
Page/Page column 51-52, (2008/06/13)
Fused pyrazoles effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.